Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 22 Feb 2024: Hengrui Medicine’s SHR-A1912 ADC gets Fast Track status from FDA Hengrui Medicine’s innovative CD79b antibody-drug-conjugate (ADC) drug, SHR-A1912, receives fast-track designation from the FDA for treating relapsed/refractory […]
Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 27 Feb 2024: 9MW2821 Receives Fast Track Designation from FDA The FDA grants Fast Track Designation to 9MW2821, a new ADC drug by Mabwell, targeting Nectin-4 for advanced esophageal squamous […]
Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 26 Feb 2024: Nona Biosciences and Boostimmune unite for Cutting-edge ADC development Nona Biosciences, a global biotechnology company, collaborates with Boostimmune to expedite Antibody-Drug Conjugates development using Harbour Mice H2L2 […]
